ArticleMilitary Medical Research2026
Global variations, temporal trends, and socioeconomic inequalities in the burden of malignant brain and central nervous system tumors: a population-based systematic analysis of GLOBOCAN 2024.
Article in Military Medical Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous assessments of the burden of malignant brain and central nervous system (CNS) tumors have mainly focused on incidence and mortality rates, with less emphasis on lifetime risks. This study aimed to estimate the incidence, mortality, and lifetime risk of developing or dying from brain and CNS tumors and the impact of socioeconomic inequality across countries. Methods: Data on brain and CNS tumors were obtained from GLOBOCAN 2024 and the Cancer Incidence in Five Continents Plus (CI5plus) database, population and death data were sourced from World Population Prospects 2024. Lifetime risk estimation was conducted using the life table method adjusted for multiple primaries. We assessed trends in brain and CNS tumors incidence, lifetime risks, and histological subtypes during 2003 to 2017. The association between the human development index (HDI) and lifetime risks was assessed using generalized linear models. Results: In 2024, the age-standardized incidence and mortality rates for brain and CNS tumors were 3.37 and 2.51 per 100,000 population, respectively. The estimated global lifetime risk of developing or dying from brain and CNS tumors, from birth to death was 0.39% and 0.32%, respectively. Significant variations in lifetime risks were observed among countries and regions, as well as across different HDI levels. The lifetime risk of developing brain and CNS tumors among countries with a low, medium, high, and very high HDI was 0.16%, 0.19%, 0.45%, and 0.59%, respectively; the risks of dying from the disease in these categories were 0.14%, 0.17%, 0.34%, and 0.48%, respectively. Histological subtypes of brain and CNS tumors showed large discrepancies among age groups and countries. The most frequently diagnosed histological type was astrocytic tumors. Conclusions: We found significant heterogeneity in the incidence, mortality, and lifetime risk of brain and CNS tumors among geographic and HDI levels, which potentially reflects disparities in medical resource allocation and genetic exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.